參考文獻(xiàn)/References:
[1] Toh C K, Ong W S, Lim W T, et al.A decade of never-smokers among lung cancer patients-increasing trend and improved survival[J]. Clin Lung Cancer,2018,19(5):e539-e550.
[2] Socinski M A, Obasaju C, Gandara D, et al.Current and emergent therapy options for advanced squamous cell lung cancer[J]. J Thorac Oncol,2018,13(2):165-183.
[3] Sacco P C, Maione P, Palazzolo G, et al.Treatment of advanced non-small cell lung cancer in the elderly[J]. Expert Rev Respir Med,2018,12(9):783-792.
[4] Choi J H, Choi J, Chung S M, et al.The clinical efficacy and safety of four-weekly docetaxel as first-line therapy in elderly lung cancer patients with squamous cell carcinoma[J]. Tuberc Respir Dis(Seoul),2018,81(3):219-225.
[5] Yardley D A.nab-Paclitaxel mechanisms of action and delivery[J]. J Control Release,2013,170(3):365-372.
[6] Socinski M A, Bondarenko I, Karaseva N A, et al.Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase Ⅲ trial[J]. J Clin Oncol,2012,30(17):2055-2062.
[7] Gridelli C, Chen T, Ko A, et al.nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase Ⅲ trial[J]. Drug Des Devel Ther,2018,12:1445-1451.
[8] Quoix E, Zalcman G, Oster J P, et al.Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial[J]. Lancet,2011,378(9796):1079-1088.
[9] Sederholm C, Hillerdal G, Lamberg K, et al.Phase Ⅲ trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group[J]. J Clin Oncol,2005,23(33):8380-8388.
[10] Mok T, Wu Y L, Kudaba I, et al.Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer(KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial[J]. Lancet,2019,393(10183):1819-1830.
[11] Paz-Ares L, Luft A, Vicente D, et al.Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med,2018,379(21):2040-2051.
相似文獻(xiàn)/References:
[1]方劍鋒.三聯(lián)療法兩種療程治療老年幽門螺桿菌陽性消化性潰瘍患者療效分析[J].福建醫(yī)藥雜志,2017,39(4):122.
[2]潘金興 姜鋒.老年2型糖尿病患者血清CA199水平及其與血糖的相關(guān)性[J].福建醫(yī)藥雜志,2017,39(5):119.
[3]林增鈺,袁 音,黃 峰,等.社區(qū)老年人空巢狀態(tài)與營養(yǎng)不良風(fēng)險(xiǎn)的相關(guān)性研究[J].福建醫(yī)藥雜志,2021,43(05):19.
LIN Zengyu,YUAN Yin,HUANG Feng,et al.Association between empty-nest status and malnutrition risk among community-dwelling elderly population[J].FUJIAN MEDICAL JOURNAL,2021,43(01):19.
[4]林燕玲,葉靜,黃淑玲,等.血清VEGF、BDNF水平與老年糖尿病大鼠認(rèn)知功能障礙相關(guān)性研究[J].福建醫(yī)藥雜志,2022,44(02):123.
LIN Yanling,YE Jing,HUANG Shuling,et al.The correlation between serum levels of VEGF and BDNF and cognitive dysfunction in elderly diabetic rats[J].FUJIAN MEDICAL JOURNAL,2022,44(01):123.
[5]莊宸麟,余惠珍陳毓岱,孫嘉峰,等.控制營養(yǎng)狀態(tài)評分與老年慢性心衰急性發(fā)作患者死亡預(yù)后的相關(guān)性研究[J].福建醫(yī)藥雜志,2023,45(02):16.
ZHUANG Chenlin,YU Huizhen,CHEN Yudai,et al.Study on the correlation between controlling nutritional status score and death prognosis in elderly patients with acute episode of chronic heart failure[J].FUJIAN MEDICAL JOURNAL,2023,45(01):16.
[6]連學(xué)輝,肖紅利,楊明,等.老年胸腰椎骨折60例術(shù)后炎癥反應(yīng)與疼痛關(guān)系分析[J].福建醫(yī)藥雜志,2023,45(02):25.